Table 4.
Baseline Demographic and Characteristics by Quartiles of RAVI/LAVI.
| Characteristic | RAVI/LAVI Q1 (<0.620) (n=29) |
RAVI/LAVI Q2 (0.620-0.840) (n=28) |
RAVI/LAVI Q3 (0.840-1.120) (n=28) |
RAVI/LAVI Q4 (≥1.120) (n=28) |
p-value |
|---|---|---|---|---|---|
| Age | 59.8 ± 15.2 | 63.3 ± 12.0 | 56.1 ± 17.6 | 60.8 ± 14.5 | 0.75 |
| Female Sex | 7 (24.1) | 7 (25.0) | 12 (42.9) | 7 (25.0) | 0.34 |
| Coronary Artery Disease | 21 (72.4) | 20(71.4) | 15 (53.6) | 16 (57.1) | 0.33 |
| Type 2 Diabetes Mellitus | 18 (62.1) | 16 (57.1) | 12 (42.9) | 10 (35.7) | 0.16 |
| Chronic Kidney Disease | 13 (44.8) | 11 (39.3) | 14 (50.0) | 13 (46.4) | 0.88 |
| Chronic Obstructive Pulmonary Disease | 8 (27.6) | 8 (28.6) | 7 (25.0) | 3 (10.7) | 0.35 |
| Hypertension | 19 (65.5) | 17 (60.7) | 14 (50.0) | 18 (64.3) | 0.63 |
| Hyperlipidemia | 16 (55.2) | 17 (60.7) | 17 (60.7) | 19 (67.9) | 0.81 |
| Tobacco Abuse | 19 (65.5) | 18 (64.3) | 15 (53.6) | 18 (64.3) | 0.77 |
| Beta Blocker | 18 (62.1) | 16 (57.1) | 20 (71.4) | 18 (64.3) | 0.73 |
| ACEi* / ARB† | 14 (48.3) | 12 (42.9) | 12 (42.9) | 15 (53.6) | 0.93 |
| Aldosterone Antagonist | 8 (27.6) | 7 (25.0) | 10 (35.7) | 7 (25.0) | 0.79 |
| Diuretic | 21 (72.4) | 17 (60.7) | 21 (75.0) | 22 (78.6) | 0.48 |
| Home Inotrope | 3 (10.3) | 1 (3.6) | 3 (10.7) | 4 (14.3) | 059 |
| Admission Lactic Acid | 2.4 ± 2.1 | 3.5 ± 2.7 | 2.6 ± 1.6 | 3.4 ± 2.3 | 0.31 |
| Admission Brain Natriuretic Peptide | 1743.2 ± 1343.9 | 1608.9 ± 1014.2 | 2454.2 ± 1919.0 | 3954.2 ± 1455.2 | 0.02 |
| Admission Creatinine | 1.6 ± 0.9 | 1.9 ± 1.2 | 1.8 ± 1.0 | 2.1 ± 1.1 | 0.19 |
a
Values are presented as mean ± standard deviation or n (%).
*
ACEi is angiotensin converting enzyme inhibitor
†
ARB is angiotensin receptor blocker.